# US Hemangioma Market

> US Hemangioma Market Research Report By Type (Capillary Hemangioma, Cavernous Hemangioma, Compound Hemangioma, Pyogenic Granuloma), By Treatment Method (Observation, Medication, Surgery, Laser Therapy), By Patient Age Group (Infants, Children, Adults, Elderly) and By End User (Hospitals, Clinics, Ambulatory Surgical Centers) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 5.89%
- **2024:** $ 168 Million
- **2025:** $ 177.9 Million
- **2035:** $ 315.29 Million
- **Key Players:** Bristol-Myers Squibb (US), Novartis (CH), Pfizer (US), Bayer (DE), Amgen (US), Eli Lilly and Company (US), Roche (CH), Sanofi (FR), Merck & Co. (US)

**Report ID:** MRFR/Pharma/17471-HCR · **Pages:** 100 · **Author:** Satyendra Maurya & Garvit Vyas · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-hemangioma-market-19017

---

## Market Summary

## **US Hemangioma Market Overview**

As per MRFR analysis, the US Hemangioma Market Size was estimated at 199.5 (USD Million) in 2023. The US Hemangioma Market Industry is expected to grow from 210 (USD Million) in 2024 to 450 (USD Million) by 2035. The US Hemangioma Market CAGR (growth rate) is expected to be around 7.174% during the forecast period (2025 - 2035).

### **Key Market Trends Highlighted**

The US Hemangioma Market is witnessing significant trends driven by advancements in medical technology and growing awareness of hemangioma among healthcare providers and patients. One key market driver is the increased focus on developing less invasive and more effective treatment options for hemangiomas, such as laser therapy and corticosteroid treatments. These innovations have emerged due to research supported by institutions like the National Institutes of Health, enhancing patient outcomes and satisfaction. Additionally, the prevalence of hemangiomas in infants, which are common vascular tumors, has led to an increase in healthcare visits, thus driving demand for specialized treatments.

There are also considerable opportunities to be explored in the hemangioma market, particularly in improving diagnostic tools and treatment protocols. The expansion of telemedicine provides new avenues for diagnosis and ongoing patient care, making it easier for parents to consult specialists without geographical limitations. Furthermore, the collaboration between medical professionals and pharmaceutical companies offers the potential to develop targeted therapies and novel drugs for more aggressive hemangiomas. Trends in recent times reflect a growing emphasis on patient-centered care, with parents increasingly seeking information and engaging in treatment decisions. 

There is also a shift toward researching the long-term effects of untreated hemangiomas, leading to a better understanding of the condition and titling treatments to minimize risks and enhance the quality of life for affected individuals. Overall, the US Hemangioma Market is evolving, creating pathways for growth through innovation, collaboration, and heightened awareness.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

## **US Hemangioma Market Drivers**

### **Increasing Awareness and Diagnosis of Hemangiomas**

The US Hemangioma Market Industry is witnessing significant growth due to increasing awareness and diagnosis of hemangiomas. In recent years, there has been a notable surge in the number of healthcare professionals and parents recognizing the condition. A study from the Centers for Disease Control and Prevention indicates that up to 10% of infants may develop infantile hemangiomas, leading to more referrals to specialists. Educational campaigns and better training for pediatricians by organizations like the American Academy of Pediatrics are helping to improve early diagnosis and treatment options, thereby enhancing patient outcomes.

As more cases are diagnosed, the market for hemangioma treatments and management solutions is projected to expand, driving overall market growth. In addition, advancements in imaging technologies are also facilitating early detection, leading to proactive management which is crucial in avoiding complications. As more knowledge about hemangiomas becomes accessible, the US Hemangioma Market Industry is expected to benefit greatly, contributing to robust market growth in the coming years.

### **Technological Advancements in Treatment Options**

The US Hemangioma Market Industry is significantly supported by ongoing technological advancements in treatment options for hemangiomas. Innovative therapies such as laser treatments, beta-blockers, and other emerging therapies are becoming more prevalent. For instance, the launch of propranolol, a beta-blocker originally used for hypertension, has been shown to effectively treat hemangiomas, leading to its increased prescription. Evidence from the National Institutes of Health suggests that propranolol can reduce the size of hemangiomas in approximately 90% of treated infants without serious side effects. Furthermore, new minimally invasive surgical techniques are becoming more common, offering effective treatment with shorter recovery times.

These advances not only improve treatment outcomes but also expand the range of options available for patients and healthcare providers, thus propelling the US Hemangioma Market Industry forward.

### **Rising Incidence of Hemangiomas**

The increasing incidence of hemangiomas in the United States is serving as a key driver for the US Hemangioma Market Industry. According to the National Hemangioma Awareness Foundation, infantile hemangiomas affect about 1 in 10 infants, with higher prevalence in females and premature babies. As the birth rate in the US was noted to be approximately 3.6 million in recent years, this translates into a significant number of new cases annually. The rising birth rates and changing demographics, as reported by the U.S. Census Bureau, are likely to contribute to a continued increase in hemangioma cases.

This growing population of affected individuals will necessitate more extensive treatment options, fueling demand in the US Hemangioma Market Industry.

## **US Hemangioma Market Segment Insights**

### **Hemangioma Market Type Insights**

The US Hemangioma Market has been experiencing significant activity, particularly in the Type segment, which includes various forms of hemangiomas. These vascular lesions are primarily classified into a few significant categories: Capillary Hemangioma, Cavernous Hemangioma, Compound Hemangioma, and Pyogenic Granuloma. Capillary Hemangiomas, often regarded as the most common type, are primarily seen in infancy and are characterized by small, red or purple marks that can resolve without treatment, which has driven interest in management strategies. 

Meanwhile, Cavernous Hemangiomas, often larger and deeper in the soft tissues, tend to be more complex and sometimes require intervention due to potential complications associated with their size and location. The importance of Compound Hemangiomas lies in their mixed composition; these lesions incorporate both capillary and cavernous structures, making them significant in clinical settings due to the variability in their presentation and management options. Pyogenic Granulomas, although not true hemangiomas, are often associated with vascular lesions and present as rapidly growing, reddish nodules that can arise from various stimuli, emphasizing the diverse nature of vascular anomalies.

This segmentation allows healthcare providers to tailor treatment based on specific characteristics and growth patterns, which is crucial for developing effective management plans.

Trends indicate that the increasing prevalence of these conditions and the ongoing Research and Development in targeted therapies contribute to a favorable outlook for the US Hemangioma Market, highlighting various avenues for medical innovation. The complexities and treatment requirements associated with these types further drive growth, as clinicians look for improved patient outcomes. Overall, the Type segment significantly impacts the broader landscape of the US Hemangioma Market by providing a nuanced view of how such lesions manifest and are managed clinically, ultimately enhancing the understanding, treatment, and patient care related to hemangiomas in various demographic settings.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

### **Hemangioma Market Treatment Method Insights**

The Treatment Method segment of the US Hemangioma Market encompasses various approaches, including Observation, Medication, Surgery, and Laser Therapy, each significant in its own right. Observation often serves as the first line of action, particularly for small, asymptomatic hemangiomas in infants that may resolve spontaneously. Medication, including corticosteroids, plays a crucial role in managing larger or symptomatic lesions, providing a non-invasive alternative. Surgery is typically reserved for complicated cases or when therapeutic response is inadequate, highlighting its importance in severe scenarios. 

Laser Therapy has gained traction for treating hemangiomas due to its precision and reduced downtime compared to traditional surgical methods, making it an appealing option for many patients. The US Hemangioma Market is experiencing growth driven by increasing awareness and the rising prevalence of hemangiomas, fueling a demand for these treatment modalities. However, challenges such as varying treatment success rates and accessibility remain, creating ongoing opportunities for innovation and improvement in the industry. Understanding the nuances within each treatment method is essential for optimizing patient outcomes and addressing specific market needs effectively.

### **Hemangioma Market Patient Age Group Insights**

The US Hemangioma Market, especially within the Patient Age Group segment, provides a rich landscape for understanding the epidemiology and treatment pathways associated with hemangiomas. Infants are particularly significant in this market as they represent a major portion of patients diagnosed with this vascular tumor, often requiring early intervention to prevent complications. Children also play an essential role in the dynamics of this market, as hemangiomas can continue to evolve during their developmental years, necessitating ongoing medical monitoring and care strategies.

Adults, while less frequently affected, still present cases that need specialized treatment options for atypical hemangiomas that may arise later in life. 

The elderly population, although younger demographics tend to dominate in prevalence, is increasingly recognized for cases of vascular lesions, thus opening up opportunities for tailored treatments in this group. Overall, the varied prevalence of hemangiomas across different age groups showcases the necessity of targeted strategies and interventions in the Hemangioma Market, highlighting the importance of understanding age-related nuances in hemangioma presentation and management. In addition, factors such as leading healthcare initiatives and innovations in treatment methods contribute to market growth and provide fresh opportunities for healthcare providers.

### **Hemangioma Market End User Insights**

The US Hemangioma Market has witnessed substantial growth, driven primarily by the increasing number of hospitals, clinics, and ambulatory surgical centers. Hospitals play a critical role, as they are equipped with advanced healthcare technologies and a comprehensive range of services that cater to patients with hemangiomas. This setting allows for proper diagnosis and timely treatment, enhancing patient outcomes. Meanwhile, clinics focus on outpatient care, providing specialized treatments that can lead to quicker recovery times and reduced hospital stays, which appeals to cost-conscious patients. 

Ambulatory surgical centers represent a significant segment due to their ability to offer surgical procedures in a more efficient and less expensive environment compared to traditional hospitals, thereby attracting a growing patient demographic. The convergence of these end-users reflects a trend towards integrated care models and patient-centered approaches, crucial for addressing the rising incidence of hemangiomas in the US population. As healthcare continues to evolve, these facilities are expected to further shape the US Hemangioma Market landscape through innovation and improved access to treatment options.

## **US Hemangioma Market Key Players and Competitive Insights**

The US Hemangioma Market is characterized by a dynamic competitive landscape with several key players vying for market share and innovation. Hemangiomas are benign tumors made up of blood vessels that commonly appear on the skin or internal organs, particularly in infants and young children. The increasing prevalence of hemangiomas and the growing awareness regarding their management have intensified competition among pharmaceutical companies to develop effective therapeutic solutions.

With advancements in biotechnology and research, the market is witnessing the emergence of new and specialized treatment options, as companies strive to differentiate themselves through innovative products, strong clinical data, and strategic collaborations.

### **Key Companies**

### **Company Profiles**

#### **Bristol Myers Squibb**

Bristol Myers Squibb has established a notable presence in the US Hemangioma Market with its commitment to research and development focused on rare diseases. The company is recognized for its robust pipeline that addresses unmet medical needs, providing effective treatment options that can significantly improve patient outcomes. Bristol Myers Squibb’s strengths lie in its extensive expertise in oncology and immunology, which allows the company to leverage its scientific capabilities to explore potential therapeutic applications for hemangiomas.

The company's significant investments in clinical trials and collaborations with healthcare professionals have further enhanced its competitive position, allowing it to remain at the forefront of innovation in this specialized market segment.

#### **Novartis**

Novartis has also made substantial contributions to the US Hemangioma Market through a strong portfolio of products and ongoing research initiatives. The company is known for developing targeted therapies that address various conditions, including hemangiomas, reflecting its commitment to advancing treatment options for patients. Novartis's strengths include a diverse range of therapeutic portfolios, a strong focus on research, and an established network for distribution and sales. The company's recent mergers and acquisitions have bolstered its market presence, enabling it to integrate advanced technologies and expertise into its product offerings.

Additionally, Novartis benefits from strategic partnerships that enhance its capabilities in developing new treatments specific to hemangiomas, positioning it as a formidable player in the competitive landscape of the US market.

## **US Hemangioma Market Industry Developments**

The US Hemangioma Market has witnessed significant developments recently, with notable growth in valuation attributed to increased diagnosis and treatment options. Companies like Bristol Myers Squibb, Novartis, and AstraZeneca are actively investing in Research and Development for novel therapeutic approaches to treat hemangiomas. In early 2023, Eli Lilly announced positive clinical trial results for its hemangioma treatment, boosting market confidence. Furthermore, in June 2023, Merck acquired a smaller biotech firm specializing in vascular disorders that include hemangiomas, enhancing its product portfolio. Meanwhile, Pfizer continues to expand its presence in the market through strategic partnerships aimed at increasing treatment accessibility. 

Current affairs point to a growing awareness of pediatric hemangiomas, leading to increased funding from governmental bodies for Research and Development initiatives. This has resulted in better screening procedures and subsequent treatment outcomes. Over the past few years, significant advancements have occurred, including the FDA’s approval of a new therapy in December 2021, which further stimulates interest in the market. The overall climate within the US Hemangioma Market indicates a dynamic shift towards innovative treatment options supported by strong growth indicators.

## **US Hemangioma Market Segmentation Insights**

### **Hemangioma Market Type Outlook**

### **Hemangioma Market Treatment Method Outlook**

### **Hemangioma Market Patient Age Group Outlook**

### **Hemangioma Market End User Outlook**

## Market Drivers

### Increased Research Funding

The allocation of research funding towards the study of hemangiomas is a critical driver for the hemangioma market. Government and private organizations are increasingly recognizing the need for comprehensive research into the causes, treatment, and management of hemangiomas. This influx of funding is expected to facilitate clinical trials and the development of new therapeutic agents, potentially leading to breakthroughs in treatment. As research progresses, it may result in the introduction of novel therapies that could reshape the landscape of the hemangioma market. The anticipated growth in research initiatives is likely to enhance the overall understanding of hemangiomas and improve patient care.

### Rising Healthcare Expenditure

The upward trend in healthcare expenditure in the US is a significant driver for the hemangioma market. As healthcare budgets expand, there is a greater focus on specialized treatments and interventions for conditions like hemangiomas. Increased spending allows for better access to advanced therapies and technologies, which can enhance patient outcomes. Furthermore, as more healthcare facilities invest in state-of-the-art equipment and training, the quality of care for hemangioma patients is likely to improve. This increase in healthcare expenditure may also encourage pharmaceutical companies to invest in research and development, further propelling the growth of the hemangioma market.

### Rising Incidence of Hemangiomas

The increasing incidence of hemangiomas in the US is a notable driver for the hemangioma market. Recent data indicates that approximately 1-3 % of infants are affected by these vascular tumors, leading to a growing demand for effective treatment options. As awareness of hemangiomas rises among healthcare professionals and parents, the need for specialized care and intervention becomes more pronounced. This trend is likely to stimulate market growth as healthcare providers seek innovative solutions to manage these conditions. Furthermore, the rising incidence may prompt further research and development initiatives, potentially leading to new therapies and treatment modalities within the hemangioma market.

### Technological Innovations in Treatment

Technological advancements in medical devices and treatment methodologies are significantly influencing the hemangioma market. Innovations such as laser therapy, cryotherapy, and advanced imaging techniques have enhanced the ability to diagnose and treat hemangiomas effectively. For instance, laser treatments have shown promising results in reducing the size of hemangiomas, thereby improving patient outcomes. The market for these advanced treatment options is projected to grow, with estimates suggesting a compound annual growth rate (CAGR) of around 5-7 % over the next few years. As these technologies become more accessible, they are likely to drive further interest and investment in the hemangioma market.

### Growing Demand for Non-Invasive Treatments

There is a notable shift towards non-invasive treatment options for hemangiomas, which is shaping the hemangioma market. Patients and healthcare providers are increasingly favoring treatments that minimize discomfort and recovery time. Non-invasive methods, such as topical medications and laser therapies, are gaining traction due to their effectiveness and reduced side effects. This trend is likely to drive market growth as more patients seek alternatives to traditional surgical interventions. The demand for these non-invasive solutions may lead to increased competition among manufacturers, fostering innovation and potentially lowering costs within the hemangioma market.

## Future Outlook

The [Hemangioma Market](https://www.marketresearchfuture.com/reports/hemangioma-market-3240) is projected to grow at a 5.89% CAGR from 2025 to 2035, driven by advancements in treatment options and increasing awareness.

**New opportunities:**

- Development of targeted therapies for pediatric patients
- Expansion of telemedicine services for remote consultations
- Investment in advanced imaging technologies for accurate diagnosis

By 2035, the market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Type: Capillary Hemangioma (Largest) vs. Cavernous Hemangioma (Fastest-Growing)

The US hemangioma market is marked by a distinct segment distribution where Capillary Hemangioma holds the largest market share, driven by its prevalence in pediatric patients. This segment benefits from effective treatment options and increased awareness among parents regarding skin lesions. On the other hand, Cavernous Hemangioma is witnessing a surge in demand due to its rising diagnosis rates and advancements in treatment modalities that cater to larger lesions, enhancing patient outcomes.  

Growth trends in this segment reveal a complex landscape influenced by factors such as the rising incidence of various hemangiomas and the increasing deployment of minimally invasive treatment techniques. Emerging technologies play a vital role in driving the growth of the fastest-growing segment, Cavernous Hemangioma, as well as advancements in laser therapies that provide effective solutions. This growth trajectory is expected to continue as healthcare systems focus more on specialized and tailored therapies.

Capillary Hemangioma (Dominant) vs. Compound Hemangioma (Emerging)

Capillary Hemangioma, as a dominant player in the US hemangioma market, is characterized by its benign nature and the propensity for spontaneous regression, which makes it a focal point in treatment protocols, particularly for infants. The market presence of this type is strong due to effective monitoring strategies and low recurrence rates. In contrast, Compound Hemangioma is emerging as a notable competitor, exhibiting mixed characteristics of both capillary and cavernous hemangiomas. Its increasing recognition can be attributed to an evolving understanding of hemangioma physiology, leading to more targeted therapeutic approaches and a greater focus on early diagnosis. As awareness grows, Compound Hemangioma is expected to capture a larger share of the market.

### By Treatment Method: Observation (Largest) vs. Surgery (Fastest-Growing)

In the US hemangioma market, the distribution of treatment methods reveals that observation leads as the largest segment, favored for its non-invasive nature. This approach is particularly prevalent among pediatric cases where careful monitoring suffices, allowing the symptoms to resolve over time without immediate intervention. Conversely, surgery has emerged as the fastest-growing segment, attracting attention for its effectiveness in removing larger and more persistent hemangiomas that do not respond to other treatments or threaten the patient’s wellbeing.

Growth trends indicate a notable shift towards surgical interventions as advancements in technology improve outcomes and reduce recovery times. The rise in surgical procedures is driven by increasing awareness of treatment options and a proactive approach among healthcare providers. Additionally, factors such as patient preference for immediate results and the effectiveness of surgery in addressing larger lesions are enhancing its market appeal, positioning it as a critical player in the evolution of treatment modalities for hemangiomas.

Observation: Dominant vs. Surgery: Emerging

The observation approach is characterized by its focus on monitoring hemangiomas without immediate therapeutic intervention, making it a dominant method especially in pediatric cases. This strategy alleviates the need for invasive measures unless complications arise, appealing to both parents and healthcare professionals for its conservative nature. On the other hand, surgery is emerging rapidly, driven by its ability to offer swift resolution for problematic hemangiomas. As surgical techniques advance, they provide enhanced safety and efficacy, resulting in higher patient satisfaction rates. The contrasting characteristics of observation and surgery showcase differing philosophies in treatment: one prioritizes watchful waiting, while the other emphasizes decisive action.

### By Patient Age Group: Infants (Largest) vs. Children (Fastest-Growing)

In the US hemangioma market, the patient age group segment shows a prominent distribution where infants hold the largest market share, highlighting a significant focus on early detection and treatment options for hemangiomas. This age group experiences a higher incidence of these vascular anomalies, which drives demand for medical attention and interventions specifically catered to younger patients. In contrast, children are emerging as the fastest-growing segment due to increasing awareness and advancements in treatment methodologies that cater to this demographic, resulting in improved health outcomes and parental concern.

Growth trends indicate that both infants and children are supported by evolving healthcare practices, driving the need for innovative solutions. The rising prevalence of hemangiomas in infants continues to provide a strong foundation for market expansion, while the children segment benefits from advancements in minimally invasive procedures and changing attitudes towards early treatment. As more healthcare providers recognize the importance of treating hemangiomas proactively, both segments are poised for significant growth within the market, with children witnessing an acceleration in treatment uptake.

Infants: Dominant vs. Children: Emerging

Infants represent a dominant segment within the US hemangioma market due to their higher prevalence of hemangiomas, leading to a robust demand for specialized care and tailored treatment approaches. Healthcare providers focus on developing pediatric-friendly interventions to address the unique needs of this age group, ensuring that treatments are safe and effective. Meanwhile, the children segment is emerging rapidly, driven by increasing awareness among parents and caregivers regarding the importance of early intervention. Enhanced diagnostic tools and treatment options, including non-surgical methods, facilitate quicker identification and management of hemangiomas, thus encouraging a growing number of families to seek timely medical attention for their children. This dynamic interplay between the dominant and emerging segments shows a vibrant market landscape geared towards innovation and patient-centric care.

### By End User: Hospitals (Largest) vs. Clinics (Fastest-Growing)

In the US hemangioma market, the distribution of market share among end users reveals that hospitals hold the largest portion due to their comprehensive facilities and expert medical staff. Clinics, while smaller in share, are rapidly gaining traction as they cater to increasing patient preferences for more accessible healthcare solutions. Ambulatory surgical centers also contribute to the market but are not as dominant in share as hospitals and clinics.

The growth trends show clinics as the fastest-growing segment, driven by a rise in minimally invasive treatment options and patient demand for convenient care. Hospitals continue to thrive as key players, offering advanced technologies and multidisciplinary teams. The overall shift towards outpatient care is pushing clinics and ambulatory surgical centers to adapt and expand their services to capture market share more effectively.

Hospitals (Dominant) vs. Clinics (Emerging)

Hospitals are characterized as dominant players in the US hemangioma market, owing to their extensive resources, specialized medical teams, and ability to handle complex cases that require comprehensive care. They provide a wide range of treatment options and have established protocols for managing hemangiomas, making them the go-to choice for patients requiring immediate and specialized attention. On the other hand, clinics are emerging as significant competitors in the market, driven by their ability to offer quicker and more accessible services. They are increasingly favored by patients seeking less invasive treatment options and faster service delivery. The growing trend of outpatient procedures is allowing clinics to expand their reach and appeal, marking their presence as a formidable segment in the hemangioma care landscape.

## Competitive Benchmarking

The hemangioma market exhibits a dynamic competitive landscape characterized by a blend of innovation, strategic partnerships, and regional expansion. Key players such as Bristol-Myers Squibb (US), Novartis (CH), and Pfizer (US) are actively shaping the market through their focused operational strategies. Bristol-Myers Squibb (US) emphasizes innovation in treatment modalities, particularly in developing targeted therapies that address specific patient needs. Meanwhile, Novartis (CH) is leveraging its extensive research capabilities to enhance its product pipeline, aiming to solidify its position in the market. Pfizer (US) is also notable for its strategic partnerships, which enhance its research and development capabilities, thereby fostering a competitive edge in the hemangioma treatment landscape.The business tactics employed by these companies reflect a concerted effort to optimize supply chains and localize manufacturing processes. The market structure appears moderately fragmented, with several players vying for market share. However, the collective influence of major companies like Amgen (US) and Eli Lilly and Company (US) contributes to a competitive environment where innovation and strategic collaborations are paramount. This fragmentation allows for diverse treatment options, catering to varying patient demographics and preferences.

In October  Amgen (US) announced a strategic collaboration with a leading biotechnology firm to develop a novel therapy for hemangiomas, which is expected to enhance treatment efficacy and patient outcomes. This partnership underscores Amgen's commitment to innovation and its proactive approach to addressing unmet medical needs in the hemangioma space. The collaboration is likely to bolster Amgen's market presence and drive future growth.

In September  Eli Lilly and Company (US) launched a new digital platform aimed at improving patient engagement and adherence to hemangioma treatments. This initiative reflects a growing trend towards digital transformation in healthcare, where technology plays a crucial role in enhancing patient experiences. By integrating digital solutions, Eli Lilly positions itself as a forward-thinking leader in the market, potentially increasing its competitive advantage.

In August  Pfizer (US) expanded its manufacturing capabilities in the US to support the production of its hemangioma treatment portfolio. This expansion not only signifies Pfizer's commitment to meeting growing demand but also enhances its supply chain reliability. Such strategic moves are indicative of a broader trend where companies are prioritizing local production to mitigate risks associated with global supply chains.

As of November  the competitive trends in the hemangioma market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence in treatment development. Strategic alliances are becoming more prevalent, fostering innovation and enhancing operational efficiencies. The shift from price-based competition to a focus on technological advancements and supply chain reliability is evident. Companies that prioritize innovation and strategic partnerships are likely to thrive in this evolving landscape, suggesting a future where differentiation is rooted in the ability to deliver cutting-edge solutions and reliable patient care.

## Recent News & Developments

The US Hemangioma Market has witnessed significant developments recently, with notable growth in valuation attributed to increased diagnosis and treatment options. Companies like Bristol Myers Squibb, Novartis, and AstraZeneca are actively investing in Research and Development for novel therapeutic approaches to treat hemangiomas. In early 2023, Eli Lilly announced positive clinical trial results for its hemangioma treatment, boosting market confidence. Furthermore, in June 2023, Merck acquired a smaller biotech firm specializing in vascular disorders that include hemangiomas, enhancing its product portfolio. Meanwhile, Pfizer continues to expand its presence in the market through strategic partnerships aimed at increasing treatment accessibility. 

Current affairs point to a growing awareness of pediatric hemangiomas, leading to increased funding from governmental bodies for Research and Development initiatives. This has resulted in better screening procedures and subsequent treatment outcomes. Over the past few years, significant advancements have occurred, including the FDA’s approval of a new therapy in December 2021, which further stimulates interest in the market. The overall climate within the US Hemangioma Market indicates a dynamic shift towards innovative treatment options supported by strong growth indicators.

## Report Scope

| MARKET SIZE 2024 | 168.0(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 177.9(USD Million) |
| MARKET SIZE 2035 | 315.29(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.89% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Bristol-Myers Squibb (US), Novartis (CH), Pfizer (US), Bayer (DE), Amgen (US), Eli Lilly and Company (US), Roche (CH), Sanofi (FR), Merck & Co. (US) |
| Segments Covered | Type, Treatment Method, Patient Age Group, End User |
| Key Market Opportunities | Advancements in minimally invasive treatments enhance patient outcomes in the hemangioma market. |
| Key Market Dynamics | Rising demand for non-invasive treatment options drives innovation in hemangioma management and therapeutic approaches. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What was the overall valuation of the US hemangioma market in 2024?**
A: The overall market valuation was $168.0 Million in 2024.

**Q: What is the projected market valuation for the US hemangioma market by 2035?**
A: The projected valuation for 2035 is $315.29 Million.

**Q: What is the expected CAGR for the US hemangioma market during the forecast period 2025 - 2035?**
A: The expected CAGR during the forecast period 2025 - 2035 is 5.89%.

**Q: Which treatment method had the highest valuation in the US hemangioma market in 2024?**
A: Surgery had the highest valuation at $60.0 Million in 2024.

**Q: What are the projected valuations for capillary hemangioma by 2035?**
A: The projected valuation for capillary hemangioma is expected to reach $95.0 Million by 2035.

**Q: Which age group is projected to have the highest market valuation in the US hemangioma market by 2035?**
A: Children are projected to have the highest market valuation at $95.0 Million by 2035.

**Q: What is the market valuation for laser therapy in the US hemangioma market in 2024?**
A: The market valuation for laser therapy was $38.0 Million in 2024.

**Q: Which key player is based in the US and is involved in the hemangioma market?**
A: Bristol-Myers Squibb is a key player based in the US involved in the hemangioma market.

**Q: What was the valuation for cavernous hemangioma in 2024?**
A: The valuation for cavernous hemangioma was $40.8 Million in 2024.

**Q: What is the projected valuation for ambulatory surgical centers in the US hemangioma market by 2035?**
A: The projected valuation for ambulatory surgical centers is expected to reach $65.29 Million by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-hemangioma-market-19017*